At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 target
Drug / intervention
Fispemifenedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study
In Brief
A Phase 2 clinical trial evaluating Fispemifene for Hypogonadism and Chronic Obstructive Pulmonary Disease. Completed, enrolled 15 participants.
Detailed Summary
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive pulmonary disease (COPD) that are on oral glucocorticoid therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Study CompletionOct 2007
First PostedFeb 2010
TodayJul 2026
First PostedFeb 3, 2010
Enrollment StartJan 1, 2007
Study CompletionOct 1, 2007
TodayJul 2, 2026
Posted 16.4 years ago
Interventions
Fispemifenedrug
once daily for 4 weeks